Purpose: The aim of this study is to compare the outcomes of intracavitary high-dose-rate brachytherapy (BT-IC) boost and external beam radiotherapy (EBRT) boost in patients treated with concomitant chemoradiotherapy for squamous cell carcinoma of the cervix. Material and methods: It is a retrospective review of 92 patients with stage IB1-IVA cervical cancer treated with concomitant chemoradiotherapy between 2008 and 2013. All patients received pelvic 3D conformal EBRT (range, 45-50.4 Gy) concomitant with weekly cisplatin (40 mg/m 2), and a BT-IC boost (37 patients: 4 fractions of 6 Gy prescribed to a point A) to the tumor or a 3D conformal EBRT boost (55 patients: 16.2 Gy), if the former was not technically feasible. Results: The 5-year overall survival and recurrence-free survival rates for both groups were 68% and 55%, respectively. The 5-year overall survival and recurrence-free survival were better and statistically significant in the BT-IC group with 82% and 79%, respectively, as compared to the EBRT group with 58% and 38%, respectively. In multivariate analysis controlling for maximum tumor dimension, lymph node status, and FIGO stage, EBRT boost was associated with a statistical significant increase in the risk of recurrence (HR: 3.56; 95%

No abstract

Background: This study evaluates long-term survival outcomes of patients submitted to surgery (with or without neck dissection) and adjuvant radiotherapy for major salivary gland tumors, as well as prognostic factors affecting clinical outcomes.Methods: Retrospective analysis was performed on patients treated for major salivary gland tumors between 2006 and 2018. Kaplan-Meier curves for disease-free survival (DFS) and overall survival (OS) were calculated, Cox regression was used for uni- and multivariate analysis to assess prognostic factors. Log-rank tests were used to compare survival outcomes according to neck dissection status, stratified by stage and by histopathological risk.Results: 38 of 77 pts were eligible for analysis. Median follow-up was 63.1 months and median dose delivered was 66 Gy. The 2- and 5-years DFS rates were 79.2% and 72%, and the 2- and 5-years OS rates were 81.5% and 66.6%, respectively. Lymphovascular invasion and neck dissection were identified as possible prognostic factors for DFS and lymphovascular invasion, positive nodes, high histopathological risk and positive margins, for OS. There were no differences observed in DFS and OS curves for high histopathological risk patients according to neck dissection. A difference was found comparing DFS on stage III-IV patients (p=0.02), OS was not different.Conclusions: DFS and OS improvements were not observed in high-risk histology and III-IV stage disease due to study limitations, regardless of neck dissection status. Some of the results shown, although with no statistically significant differences, could reveal the potential of adjuvant radiotherapy in pts unable to perform neck dissection.

No abstract

No abstract